Venture Backed Life Sciences Up Rounds Top Down Rounds In 2012


Valuations are strong for venture-backed enterprise companies and Internet startups with top prospects. What about health care?

Turns out 2012 was a relatively solid year there, too. Up rounds outpaced down rounds 52% to 17% over the 12 months, with 31% of deals holding steady on valuation, according to study from Fenwick & West. This is a modest improvement from 2011 when 47% of venture capital health care deals were up rounds and 25% saw valuations decline.

Fenwick & West said it analyzed 363 financings in its 2012 Life Science Venture Capital Survey.

Overall, the study found an average 23% increase in private company share price in 2012, a step up from the 14% increase in 2011.

The life-sciences funding environment remains difficult. But perhaps venture capitalists are more confident about the companies they do fund.

Photo courtesy of Shutterstock.

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.